Entering text into the input field will update the search result below

BioTime, Inc. (BTX) CEO Aditya Mohanty on Q2 2018 Results - Earnings Call Transcript

Aug. 02, 2018 11:57 PM ETLineage Cell Therapeutics, Inc. (LCTX)2 Comments
SA Transcripts profile picture
SA Transcripts

BioTime, Inc. (BTX) Q2 2018 Earnings Conference Call August 2, 2018 4:30 PM ET


David Nakasone - IR

Aditya Mohanty - Co-CEO, President & Director

Michael West - Co-CEO & Director

Russell Skibsted - CFO


Reni Benjamin - Raymond James

Patrick Lin - Primarius Capital

Bruce Jackson - Benchmark


Good day, ladies and gentlemen, and welcome to the BioTime's Second Quarter 2018 Earnings Conference Call. [Operator Instructions]. And as a reminder, today's conference is being recorded. I would now like to turn the call over to Mr. David Nakasone. Sir, you may begin.

David Nakasone

Thank you, Operator, and good afternoon, everyone. Thank you for joining us today for BioTime's investor conference call and webcast to review the company's results for the second quarter of 2018 as well as recent corporate developments. BioTime issued the second quarter earnings release earlier this afternoon. The earnings release is posted and available on our website at www.biotime.com. There will be a replay of this call, which will be available approximately two hours after the call's conclusion and will remain available for 7 days. The operator will provide the replay information at the end of today's call.

With us today at corporate headquarters are Co-Chief Executive Officer, Adi Mohanty; and Chief Financial Officer, Russell Skibsted. Co-Chief Executive Officer, Dr. Michael West, will be joining us from New York. Each executive will make prepared remarks, and then we will take your questions from our covering analysts and institutional holders.

Before we get started, we would like to remind you that, during the course of this conference call, the company will make projections and forward-looking statements regarding future events. We encourage you to review the company's filings with the SEC, including without limitation to the company's form 10-K and 10-Q, which identify the specific factors that may cause actual

Recommended For You

Comments (2)

credibility check - if Renevia has a high percentage chance of being significantly valuable then why is it difficult to find a large pharma partner now ? Allergen should be ringing your phones off their hook and structure a exclusive collaborative agreement with milestone payments and a percent of possible revenue. Is the phone ringing ? If not thence maybe BTX should be making the phone calls
Great call. Need positive movement in the drug approval process to increase the share price or a large pharmaceutical partner. How about partnering Renevia ?
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.